Washington: Pfizer Inc and partner BioNTech SE’s COVID-19 vaccine candidate produced no severe allergic reactions during clinical trials, a Pfizer executive said at a regulatory conference on Friday.
According to Dr William Gruber, Pfizer’s senior vice president of vaccine clinical research and development, a late-stage trial testing the potential vaccine excluded participants who had a prior history of severe allergic reactions to any vaccine or to the constituents of Pfizer/BioNTech vaccine.
“We’ve not had any anaphylactic episodes related to the vaccine,” Gruber was quoted as saying during a panel meeting of independent advisers to the US Centres for Disease Control and Prevention by news agency Reuters.
According to Pfizer executive Susan Mather, the trial included about 6,000 participants respectively in both the vaccine and placebo groups with a history of a range of allergic conditions like pollen allergy, food allergy, all the way up to anaphylaxis.
